Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
2016 — A year of data integrity issues and pharma non-compliances
Data integrity was a hot topic of discussion in the pharmaceutical industry throughout 2016. Largely
